CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
Epilepsy research 2019 May 154 139-143.
Chen Lanlan, Tian Qiuxiang, Zhang Miaoran, Chen Deyu, Gao Xue, Yang Hongqun, Li Haitao, Li Chengnan, Wen Jianping, Li Yulin, Tian Xin, Chen Pe
4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Epilepsy research 2014 Aug 108 (6): 1046-51.
Inoue Kazuyuki, Suzuki Eri, Takahashi Toshiki, Yamamoto Yoshiaki, Yazawa Rei, Takahashi Yukitoshi, Imai Katsumi, Miyakawa Kou, Inoue Yushi, Tsuji Daiki, Hayashi Hideki, Itoh Kunihi